AMH Equity Ltd Grows Stock Position in SCYNEXIS, Inc. (NASDAQ:SCYX)

AMH Equity Ltd boosted its stake in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) by 4.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 626,052 shares of the company’s stock after acquiring an additional 26,052 shares during the quarter. AMH Equity Ltd owned 1.65% of SCYNEXIS worth $758,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Geode Capital Management LLC lifted its position in SCYNEXIS by 10.0% in the third quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after purchasing an additional 36,405 shares during the last quarter. Institutional investors and hedge funds own 54.37% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of SCYNEXIS from a “sell” rating to a “hold” rating in a report on Friday, November 8th.

SCYNEXIS Trading Up 1.0 %

SCYX stock opened at $1.02 on Thursday. The stock has a market capitalization of $38.71 million, a price-to-earnings ratio of -1.38 and a beta of 1.52. The firm’s 50-day moving average price is $1.12 and its two-hundred day moving average price is $1.31. SCYNEXIS, Inc. has a 12-month low of $0.90 and a 12-month high of $3.07.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.